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Control the Host Cell Cycle: Viral Regulation of the Anaphase-
Promoting Complex
Anthony R. Fehr, Dong Yu
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA
Viruses commonly manipulate cell cycle progression to create cellular conditions that are most beneficial to their replication. To
accomplish this feat, viruses often target critical cell cycle regulators in order to have maximal effect with minimal input. One
suchmaster regulator is the large, multisubunit E3 ubiquitin ligase anaphase-promoting complex (APC) that targets effector
proteins for ubiquitination and proteasome degradation. The APC is essential for cells to progress through anaphase, exit from
mitosis, and prevent a premature entry into S phase. These far-reaching effects of the APC on the cell cycle are through its ability
to target a number of substrates, including securin, cyclin A, cyclin B, thymidine kinase, geminin, andmany others. Recent stud-
ies have identified several proteins from a number of viruses that canmodulate APC activity by different mechanisms, highlight-
ing the potential of the APC in driving viral replication or pathogenesis. Most notably, human cytomegalovirus (HCMV) protein
pUL21a was recently identified to disable the APC via a novel mechanism by targeting APC subunits for degradation, both dur-
ing virus infection and in isolation. Importantly, HCMV lacking both viral APC regulators is significantly attenuated, demon-
strating the impact of the APC on a virus infection. Work in this field will likely lead to novel insights into viral replication and
pathogenesis and APC function and identify novel antiviral and anticancer targets. Here we review viral mechanisms to regulate
the APC, speculate on their roles during infection, and identify questions to be addressed in future studies.
Viruses oftenmodulate the cell cycle to their advantage in orderto provide the proper resources and conditions for their rep-
lication (1). As viral genomes are limited in their coding capacity,
viruses target cellular processes where they can exert a maximal
effect with relatively few activities. Studies of viral interactions
with the host cell cycle have not only shed light on themechanisms
of virus replication and pathogenesis, they have also led to the
identification and characterization of essential cell cycle regula-
tors, such as p53 and Rb (2–5). Another important protein com-
plex involved in cell cycle control is the anaphase-promoting com-
plex (APC), an E3 ubiquitin ligase required for ubiquitination and
subsequent proteasome degradation of multiple cell cycle regula-
tor and effector proteins. Without the APC, cells cannot separate
sister chromatids during anaphase, exit mitosis, or properly enter
S phase (6). Due to its essential role in cell cycle progression, it is
not surprising that several viruses have been recently reported to
target the APC. Perhaps the most notable example is human cy-
tomegalovirus (HCMV). A recent study has identified the HCMV
protein pUL21a as a novel viral regulator that induces degradation
of APC subunits during virus infection (7). Abrogation of the viral
ability to disable APC activity results in a marked attenuation in
HCMV infection, thus demonstrating for the first time the role of
a viral APC regulator in the context of virus infection (7). Inter-
estingly, some viruses that encode APC regulators are known to
cause cancer or are associated with cancer, suggesting that virus-
altered APC activity may be involved in the development of virus-
induced tumors. Studies of these proteins will likely impart in-
sights into viral replication and pathogenesis and lead to novel
targets for antiviral therapeutics. Perhaps equally important, as
was the case with p53 and Rb, these viral proteins may prove to be
excellent tools to study APC biology. As the APC is now emerging
as an attractive anticancer drug target (8), these studies may ulti-
mately allow us to exploit these viral regulators and identify novel
mechanisms targeting the APC for cancer therapies. Here we will
review what is known about viral APC regulators, speculate as to
why viruses might disarm the APC, and discuss questions which
need to be addressed in future research. A particular emphasis is
given to the most recent discovery of the novel APC regulator in
HCMV.
ANAPHASE-PROMOTING COMPLEX
Structure. The APC is a multisubunit E3 ubiquitin ligase that
targets more than 30 proteins for ubiquitin-dependent protea-
some degradation (9). E3 ubiquitin ligases are a large class of en-
zymes which catalyze the final step in the ubiquitin transfer reac-
tion, namely, the transfer of ubiquitin from an E2 ubiquitin ligase
to a target protein. Themajority of APC substrates are involved in
cell cycle regulation, making the APC an essential regulator of the
cell cycle.
The human APC is an approximately 1.5-MDa complex that
contains at least 12 subunits and two coactivators (Fig. 1). It can be
broken down into three subcomplexes: the enzymatic unit, the
specificity arm, and the bridge. The major components of the
enzymatic unit are APC2, APC10 (also called Doc1), and APC11.
The APC is a cullin-RING E3 ubiquitin ligase in which the cullin
and RING domains reside within APC2 and APC11, respectively
(10, 11). APC10/Doc1 plays an important role in identifying spe-
cific substrates (12, 13). On the opposite side of the enzymatic unit
is the specificity arm that ismade up of APC3 (also calledCDC27),
APC6, APC7, APC8, APC12 (CDC26), APC13, andAPC16. These
proteins contain multiple copies of the tetratricopeptide repeat
(TPR) that likely facilitate complex assembly as well as substrate
binding (6). Consequently, the specificity arm is also known as the
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TPR subunits. These two subcomplexes are held together by the
bridge that is composed of APC1, APC4, and APC5.Why the APC
is so large and contains so many subunits remains elusive, but it is
sensible to speculate that its large size allows theAPC the flexibility
to target a wide range of substrates for ubiquitin conjugation.
Regulation. APC activity is regulated by two coactivator pro-
teins, cell division cycle protein 20 (Cdc20) andCdc20 homologue
1 (Cdh1). These two activator proteins act at different times to
regulate APC activity, allowing it to exert distinct functions at
different phases of the cell cycle (Fig. 2). Cdc20 functions from
metaphase through anaphase to promote separation of sister
chromatids, while Cdh1 is active from the end of mitosis until the
G1-to-S transition to prevent premature entry into S phase. The
precise mechanism of how the activator proteins function is un-
known, but it is thought that they enable the APC to bind to its
specific substrates (14).
Cdc20 and Cdh1 are both tightly regulated to ensure that they
function precisely at different times during the cell cycle (15–20).
Mitotic kinases phosphorylate Cdc20 during metaphase to pro-
mote its association with the APC. However, the Cdc20-contain-
ing APC complex (APCCdc20) is kept inactive by the spindle as-
sembly checkpoint (SAC)until the spindle poles align (21).On the
other hand, Cdh1 is inactivated by phosphorylation and remains
inactive until cyclin-dependent kinase (CDK) activity diminishes
in latemitosis. The Cdh1 complex (APCCdh1) is highly active inG1
phase and is then inhibited by early mitotic inhibitor 1 (Emi1)
during the G1-to-S transition (22). Finally, the APC also under-
goes feedback regulation, as APCCdh1 itself can target Cdc20 and
Cdh1 for proteasome degradation (23–27). As a result, during the
late stages of mitosis, the APCCdh1-mediated degradation of
Cdc20, together with the diminishment of CDK activity, is
thought to facilitate the transition from APCCdc20 to APCCdh1.
Conversely, the APCCdh1-mediated degradation of Cdh1 and its
E2 enzyme UbcH10, together with Emi1 induction and increased
CDK activity, diminishes and inactivates APCCdh1 upon entering
S phase.
Targets. The APC targets more than 30 proteins for polyubiq-
uitination and proteasome degradation. The two best-knownmo-
tifs that the APC recognizes in its target proteins are the D box
(RXXLXXXXN/D/E) (28–30) and the KEN domain (KEN) (31,
32). Some of the well-known substrates include cyclin A, cyclin B,
and securin. The degradation of the cyclins during mitosis re-
FIG 1 Structure of the APC. (A) Schematic structure of the APC. The APC is composed of three distinct subcomplexes that are color-coded for easy
identification. The enzymatic unit (purple) contains the cullin andRINGdomains, which reside inAPC2 andAPC11, respectively. The specificity arm (also called
the TPR subunits [green]) facilitates complex assembly as well as substrate binding. The bridge (pink) holds the other subcomplexes together. The coactivators
(brown) bind to both the enzymatic unit and the specificity arm, where they interact with substrates. For clarity, the diagram is not drawn to scale and not all
subunits are shown. (B) The humanAPC structure derived from single-particle electronicmicroscopic analysis and three-dimensional (3D) reconstruction (73).
Shown are the triangular architecture of the APC and the locations of representative subunits of the specificity arm (i.e., APC3/CDC27, APC16, and other TPR
subunits), enzymatic unit (i.e., APC2 andAPC10/Doc1), and bridge (i.e., APC1, APC4, andAPC5). The red arrow depicts the binding site of the APC coactivator
(e.g., Cdh1, which is not shown in the image).
FIG 2 General function and key targets of the APC. The eukaryotic cell cycle
is divided into four phases, mitosis (M), Gap1 (G1), DNA synthesis (S), and
Gap2 (G2). The APC interacts with the coactivator Cdc20 or Cdh1 to form
APCCdc20 or APCCdh1, respectively, the two of which act on different phases of
the cell cycle. APCCdc20 starts to form toward the end of G2 phase as CDK
activity increases, but its activity is inhibited by the spindle assembly check-
point (SAC) until anaphase. Once active, APCCdc20 degrades securin, cyclin
B1, and others to promote the completion of M phase. APCCdc20 activity then
diminishes in late M phase with the drop in CDK activity and degradation of
Cdc20 by APCCdh1. In contrast, APCCdh1 is formed in late M phase and main-
tains high activity throughout G1. It targets a number of proteins, including
cyclin A2, geminin, ribonucleotide reductase (RRM2), thymidine kinase (TK),
and others, for degradation to prevent premature entry into S phase. APCCdh1
must be inhibited before S phase can begin. It is inhibited by Emi1, CDK
activity, and a negative feedback loop in which it targets Cdh1 for degradation.
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duces CDK activity. This promotes the disassembly of the mi-
totic spindle, chromosome decondensation, reformation of the
nuclear envelope, and formation of a cytokinetic groove (33–
35). Securin binds and inhibits separase, an enzyme that cleaves
cohesin to separate sister chromatids. Thus, degradation of
securin by APCCdc20 allows for activation of separase, segrega-
tion of sister chromatids, and initiation of anaphase (reviewed
in reference 36). In addition, the APC has many other targets
involved in a variety of functions central to the cell cycle. These
include but are not limited to mitotic kinases (aurora kinase
A and B, polo-like kinase [PLK-1]), DNA replication (Cdc6
and geminin), nucleotide biosynthesis (thymidine kinase [TK],
ribonucleotide reductase [RRM2], and deoxythymidylate ki-
nase), glycolysis (6-phosphofructo-2-kinase/fructose-2,6-bis-
phosphatase isoform 3 [PFKFB3]), and glutaminolysis (gluta-
minase 1) (37) (Fig. 3).
MODULATION OF THE APC BY VIRUSES
As many viruses manipulate the cell cycle during infection and
some of them cause tumors, it is not surprising that the APC
would be targeted by viruses. An accumulating body of literature
in recent years has identifiedmultiple viral proteins that canmod-
ulate the function of the APC. They do so via a diverse array of
mechanisms, highlighting the fact that viruses have gained the
ability tomodulate this important host factor through convergent
evolution. Most recently, the HCMV pUL21a protein was found
to disrupt the APCby proteasome-dependent degradation of APC
subunits. Other documented viral APC regulators include adeno-
virus (AdV) E4orf4 and E1A, human T-lymphotropic virus type 1
(HTLV-1) Tax, human papillomavirus (HPV) E2, hepatitis B vi-
rus (HBV) X, chicken anemia virus (CAV) apoptin, orf virus pox-
virus APC/cyclosome regulator (PACR), and HCMV pUL97
(summarized in Table 1 and Fig. 4). Intriguingly, a number of
these viruses are either oncogenic (HTLV-1, HPV, HBV) or po-
tentially associated with cancer (HCMV). Here we discuss the
mechanisms that these viral proteins use to control the APC and
identify questions that need to be addressed in future studies in
order to understand the role of APC regulation in the biology and
pathogenesis of these viruses.
Adenovirus E4orf4. Adenoviruses are a family of double-
stranded DNA viruses that cause a variety of clinical illnesses, in-
cluding upper respiratory infections, conjunctivitis, tonsillitis,
and gastroenteritis in mammalian species. Intriguingly, even
though it is not known to be oncogenic in humans, in tissue cul-
ture, human adenovirus (HAdV) can induce cellular transforma-
tion. HAdV encodes the protein E4orf4, which, when overex-
pressed, can institute a cell cycle block at G2/M phase and induce
apoptosis of cancer cells. These effects are dependent on its bind-
ing to protein phosphatase 2A (PP2A) (reviewed in reference 38).
The E4orf4-PP2A complex also interacts with the APC to alter its
activity (39, 40). However, the binding site andmechanism that it
uses to regulate the APC remain unknown (39). E4orf4 overex-
pression alters APC activity in both yeast and human cells, and
these effects can be both stimulatory and inhibitory, depending on
the stage of the cell cycle in which the protein is expressed (39, 40).
However, it has not yet been shown that this regulation of the APC
occurs during adenovirus infection. E4orf4 is nonessential for
virus replication in cultured human cancer or primary cells, so
how this protein impacts adenovirus biology remains elusive (41).
FIG 3 APC substrates that may impact virus replication. There are more than
30 known protein substrates of the APC, and selected candidates that have
potential to impact viral infection due to their specific role in host cell cycle
progression are listed.
TABLE 1 Viral regulators of the APC





HTLV-1 Yes Tax Unknown—binds to and activates the APC; may affect
APC3/CDC27 phosphorylation
No No 33, 38
HBV Yes X Binds to BubR1—promotes the association of Cdc20
with core APC subunits to activate the complex
No No 21
Adenovirus Noa E4orf4 Unknown—requires the interaction with PP2A No No 24, 42
Noa E1A Binds to CBP/p300 and displaces the APC from
CBP/p300
No No 65
HPV Yes E2 Binds directly to Cdh1/Cdc20; redistributes Cdh1 to
insoluble cytoplasmic structures
No No 2
Orf virus No PACR APC11 decoy No No 40, 41
CAV No Apoptin Likely binds to APC1, redistributes the APC to PML
bodies, and causes the dissociation of the APC
No No 16, 60
HCMV Potential association pUL97 Phosphorylates Cdh1 Yes No 62
Potential association pUL21a Binds to the APC; targets APC4 and APC5 for
proteasome degradation, leading to dissociation of
the APC
Yes Yes 8
a Adenovirus is not known to cause cancer in humans, but it can induce tumors in rodents and transform rodent cells in culture.
Minireview





ber 1, 2014 by W






Determining whether E4orf4 inhibits the APC during infection,
elucidating its consequence on virus replication, and identifying
its mechanism of action are key questions to address in future
studies.
Adenovirus E1A. The E1A protein can transform primary ro-
dent cells in tissue culture. It does so by multiple mechanisms,
including its ability to bind and inhibit pRb. In fact, the discovery
of the interaction between E1A and pRb was the first example of
an oncogene and a tumor suppressor gene that physically interact
(5). Moreover, E1A binds to the cyclic AMP response element
binding protein (CBP) and p300, and these interactions are also
required for the transforming capability of E1A (42, 43). CBP/
p300 are large lysine acetyltransferases that act as transcriptional
coactivators via chromatin modification. Consistently, E1A has
been reported to be able to modulate the methylation/acetylation
status of E2F promoters and induce transcription of E2F-respon-
sible genes required for S-phase entry (44). It was later discovered
that APC5 and APC7 were able to complex with CBP/p300 be-
cause they contained E1A-like protein interaction domains (45).
The binding of APC5/APC7 to CBP/p300 appeared to be impor-
tant for their functions, as expression of APC5/APC7 or APC ho-
loenzyme-stimulated CBP/p300 activity and knockdown of CBP
inhibited APC ubiquitin ligase activity (45). Importantly, APC5/
APC7 overexpression limited the transforming ability of E1A
whereas APC5/APC7 knockdown was able to enhance the trans-
forming ability of an otherwise transformation-deficient E1Amu-
tant that was unable to bind to CBP/p300 (45). These studies have
led to the model in which E1A disrupts the interaction of the APC
and CBP/p300 to disable their functions. This ultimately leads to
inhibition of gene transcription involved in G1 arrest and activa-
tion of gene transcription required for S-phase entry and cellular
DNA synthesis (46). However, no studies have been documented
to directly examine how E1A affects APC activity, so the effects of
overexpression or knockdown of APC components may be indi-
rect. Biochemical data will be critical to determine if E1A specifi-
cally disrupts the activity of a CBP/p300-APC complex.
HTLV-1 Tax.Human T-lymphotropic virus type 1 (HTLV-1)
is the etiologic agent of T cell leukemia and lymphoma. Patholog-
ical findings have shown that mitotic aberrations accompany
HTLV-1 viral replication, whichmay promote tumorigenesis (47,
48). HTLV-1 transformed T cells are delayed in their progression
through the S/G2/M phases of the cell cycle, and this delay corre-
lates with a decrease in several APC substrates (49). Moreover,
APCCdc20 is prematurely activated in Tax-expressing cells. Tax
interacts with both Cdc20- andCdh1-containing APC complexes,
suggesting that it likely binds to a core subunit of the APC, but the
mechanismof its action remains unknown (49). Tax expression in
Saccharomyces cerevisiae cells results in the reduction of APC sub-
strates and severe chromosomal abnormalities and can lead to
senescence (50, 51). Furthermore, point mutants of Tax that have
specifically lost the ability to regulate the APC are also unable to
induce senescence in HeLa and yeast cells (52). Collectively, these
studies suggest that Tax enhances APC activity, which may be
linked to its ability to induce mitotic aberrations. Further experi-
ments with these mutants are needed to determine if Tax-medi-
ated APC regulation is important for HTLV-1-induced tumors.
HPV E2. Human papillomavirus (HPV) is a small DNA virus
that causes cervical cancers. Different strains of HPV can be di-
vided into low-risk and high-risk groups for their ability to pro-
mote cervical cancer. Bellanger and colleagues found that HPV E2
proteins from high-risk but not low-risk strains were capable of
inducing a mitotic block and subsequent apoptosis (53). Interest-
ingly, cells that overcame this block developed severe genomic
instability. Furthermore, they showed that E2 proteins from high-
risk strains can bind directly to Cdh1 and Cdc20, induce the ac-
cumulation of APC substrates, and redistribute Cdh1 to insoluble
cytoplasmic aggregates (53). This suggests that inhibition of the
APCmay be onemechanism forHPV to promote tumors. It is not
known, however, whether E2-induced genomic instability is the
direct result of APC inhibition or can be attributed to other func-
tions of this multifunctional protein. As E2 is required for viral
DNA synthesis, APC regulation may also be important for the
virus to replicate its genome (54). A mutant E2 protein that spe-
cifically abrogates its ability to inhibit the APC is crucial to eluci-
date the role of APC regulation in HPV replication and carcino-
genesis.
HBVX.Hepatitis B virus (HBV) is one of the primary etiolog-
ical factors for the development of hepatocellular carcinoma
(HCC), the possible outcome of virus-induced chromosome in-
FIG 4 Viral regulators of the APC. Depicted are known viral APC regulators
and mechanisms by which they regulate the APC (see also Table 1). HCMV
pUL97 phosphorylates Cdh1, rendering it unable to bind the APC. HPV E2
binds directly to Cdh1 and Cdc20 to relocalize them to insoluble cytoplasmic
structures. Orf virus PACR acts as a nonfunctional mimic to displace APC11.
CAV apoptin interacts with the APC, redistributes it to PML bodies, and
causes it to dissociate. Adenovirus E1A likely blocks the interaction of the APC
with CBP/p300 by competing with APC5/APC7 for binding to CBP/p300.
HCMV pUL21a interacts with the APC and targets the bridge subunits APC4
and APC5 for proteasome-dependent degradation, leading to dissociation of
the complex. Adenovirus E4orf4 can either inhibit or activate the APC and
does so in a PP2A-dependent manner; however, a detailed mechanism is un-
known. HTLV-1 Tax binds to and activates the APC during S phase, but the
mechanism by which it activates the APC remains unknown. HBV X protein
activates the APC through its interaction with BubR1, which releases the co-
activator Cdc20 from the SAC, allowing premature activation of the APC.
Arrows in green and red depict the activation and inhibition of the APC by a
viral protein, respectively. Question marks indicate that a mechanism is
unknown.
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stability. Kim and colleagues reported that the HBV X protein
bound toBubR1, a component of the spindle assembly checkpoint
(SAC) (55). The binding of BubR1 was mapped to the C terminus
of X, which was also critical for the X protein to promote aberrant
chromosomes (55). The binding of X to BubR1 prevented Cdc20
from binding to BubR1. This released Cdc20 from the spindle
assembly checkpoint and allowed it to prematurely activate the
APC prior to spindle pole alignment, thus having the potential to
induce aberrant chromosome segregation. However, the X pro-
tein has also been shown to bind the E3 ubiquitin ligase damaged
DNA binding protein 1 (DDB1), and this activity may play a
prominent role in its induction of chromosome instability (56).
Thus, more-definitive evidence is needed to determine if X-medi-
atedAPC regulation plays a role inHBV-mediated carcinogenesis.
CAV apoptin. Chicken anemia virus (CAV) is a small, single-
stranded DNA virus that causes severe anemia and immunodefi-
ciency in young chickens by inducing apoptosis of erythroblastoid
cells and cortical thymocytes. Apoptin, one of the three proteins
encoded by this virus, induces a strong G2/M arrest and subse-
quent apoptosis of cancer cells (57). Its ability to specifically kill
cancer cells has made it an attractive candidate for novel cancer
therapies (1). Teodoro and colleagues identified APC1 as a bind-
ing partner of apoptin by coimmunoprecipitation (co-IP)-mass
spectrometry analysis (57). Although it has not yet been con-
firmed, APC1 is likely to be a direct binding partner, as it was the
only protein identified from this analysis. Apoptin expression led
to dissociation of the APC and stabilization of APC substrates
(57). A subsequent study showed that apoptin induced the forma-
tion of promyelocytic leukemia (PML) nuclear bodies and relo-
calized the APC to PML bodies and that these activities were de-
pendent on its ability to shuttle between the nucleus and
cytoplasm (58). The APC binding domain was mapped to the
C-terminal 40 amino acids of apoptin, which is also sufficient to
induce apoptosis (57). This suggests that the induction of apop-
tosis by apoptin may depend on its ability to regulate the APC. To
support this hypothesis, small interfering RNA (siRNA) knock-
down of APC1 induced G2/M arrest and apoptosis in a manner
similar to that by apoptin (57). Future work should address how
apoptin induces the dissociation of the APC and whether this
requires its redistribution to PMLbodies. Interestingly, while apo-
ptin-null CAV is defective in DNA synthesis, an apoptin point
mutant of CAV is capable of synthesizing viral DNA but fails to
produce virus particles (59). Thus, it will also be important to
determine whether APC depletion by siRNA restores DNA repli-
cation or particle formation in thesemutants in order to define the
potential role of APC regulation in CAV replication.
Orf virus PACR. Orf virus is a parapoxvirus which causes an
exanthemous disease in sheep and goats. A recent study byMoand
colleagues identified a poxvirus protein with significant sequence
homology to APC11 (60). Termed PACR (poxviral APC/C regu-
lator), this protein is present only in the parapoxvirus family. It
binds APC2 in a manner that mimics APC11, but it lacks the
catalytic residues of an E3 ligase, and thus, its enzymatic domain is
nonfunctional and does not contain ubiquitin ligase activity (60,
61). Importantly, swapping the enzymatic domains of APC11 and
PACR also reverses their ubiquitin ligase activity in vitro. PACR
overexpression leads to a G2/M arrest with an increase in APC
substrates, supporting the notion that PACR inhibits the APC by
mimicking a nonfunctional APC11. PACR-null orf virus has a
nearly 100-fold growth defect.While this defect is likely due to the
ability of PACR to inhibit the APC, analyzing domain swap re-
combinant viruses or examining orf virus infection in APC-de-
pleted cells will provide definitive evidence to test this hypothesis.
HCMV pUL97.HCMV is a large, double-stranded DNA virus
that establishes persistent and latent infection in humanhosts. It is
a common source of severe infectious complications in immuno-
compromised individuals and the leading viral cause of birth de-
fects. Moreover, accumulating evidence suggests a possible link of
HCMV with certain human cancers (62–64). HCMV uses multi-
ple mechanisms to modulate the function of the APC (65–67).
One mechanism is to induce Cdh1 phosphorylation. Tran and
colleagues reported that the viral protein kinase pUL97 was re-
sponsible for Cdh1 phosphorylation during HCMV infection
(65). pUL97 is a CDKmimic (68, 69), so it is not surprising that it
is able to phosphorylate Cdh1, a natural target of CDKs. In cells
infectedwith aUL97 deletion virus, Cdh1was not phosphorylated
and APC substrate accumulation was delayed at early times com-
pared to cells infected with wild-type virus (65). However, by the
times when viral DNA synthesis occurred (i.e., 24 to 36 h postin-
fection), the APC substrates accumulated efficiently even in the
absence of pUL97. This indicates that HCMV must have addi-
tional mechanisms to regulate the APC. It is currently unclear
whether the inhibition of the APC by pUL97 alone plays a role in
the ability of HCMV to replicate or cause disease.
HCMV pUL21a. In addition to pUL97, it is clear that HCMV
encodes at least one other factor that can regulate the APC by
inducing its dissociation. Tran and colleagues analyzed APC sub-
units and found that APC4 and APC5 were degraded indepen-
dently of pUL97 in a proteasome-dependent manner during
HCMV infection (65). APC4 and APC5 degradation is likely to
lead to dissociation of the APC complex, as this dissociation is
prevented by proteasome inhibitors. In a proteomics screen for
interacting partners of the HCMV protein pUL21a, multiple sub-
units of theAPC, includingAPC3/CDC27, APC7, andAPC8,were
identified (7). pUL21a is a 15-kDa protein that shares no signifi-
cant homology with any known protein (70), and pUL21a-null
virus had amarked defect in viral DNA synthesis (71). Subsequent
functional analysis indicated that pUL21a was both necessary and
sufficient to target APC4 and APC5 for proteasome degradation,
leading to dissociation of the complex (7). A pUL21a point mu-
tant, PR109-110AA (herein termed pUL21aPR-AA), that was not
able to bind the APC failed to target APC4/APC5 for degradation,
indicating that the ability of pUL21a to degrade APC4/APC5 is
dependent on its binding to the APC. Incidentally, pUL21a itself is
highly unstable, undergoing rapid turnover in a proteasome-de-
pendent, ubiquitin-independent manner (70). It is possible that
pUL21a recruits an E3 ligase to the APC to promote ubiquitina-
tion of APC4 and APC5. Alternatively, it is intriguing to speculate
that pUL21amay act as a ubiquitin-like protein and directly target
these APC subunits to the proteasome for degradation. In future
studies, it will be important to identify the APC subunit that
pUL21a directly interacts with, elucidate themechanism bywhich
pUL21a degrades APC4 and APC5, and determine whether the
intrinsic instability of pUL21a plays a role in its ability to regulate
the APC. It is interesting to note that both CAV apoptin and
HCMVpUL21a regulate the APC by targeting the bridge subcom-
plex and inducing its dissociation. This is consistent with the crit-
ical function of the bridge subcomplex in maintaining APC sta-
bility and suggests a conserved strategy evolved by different
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viruses converging on this subcomplex as an efficient means to
regulate APC activity.
What is the role of pUL21a-mediated APC regulation in
HCMV infection? Compared to cells infected with wild-type
HCMV, cells infected with UL21a-null virus or the pUL21aPR-AA
point mutant virus had much-reduced levels of a subset of APC
substrates, but not all APC substrates were affected. This may
result from two potential mechanisms which are not mutually
exclusive. Modulating the APC complex by dissolving the bridge
may allow viruses to alter substrate specificity of the APC but not
completely abolish its activity, as the enzymatic portion of the
APC is known to have activity in vitro (10, 60). HCMV does not
appear to directly destroy the enzymatic unit of APC, so it is of
interest to determine if the APC retains some activity or is directed
to target different substrates during virus infection. Alternatively,
as Cdh1 is phosphorylated by pUL97 during infection,UL21amu-
tant virus may still inhibit the APC to some extent. This supports
the model that HCMV uses two distinct mechanisms, one medi-
ated by pUL21a and the other mediated by pUL97, to regulate the
APC. This is further exemplified by the growth kinetics of the
pUL21aPR-AA point mutant virus. This mutant virus grew at wild-
type levels, but a double mutant virus that carried both the
pUL21aPR-AA point mutation and a UL97 deletion was signifi-
cantly more attenuated than a UL97 single-deletion virus (7).
Therefore, the consequence of pUL21a-mediated APC regulation
to HCMV replication is apparent only when both viral APC reg-
ulators are removed from the virus. These data support the hy-
pothesis that the APC is a restriction factor for HCMV, but this
restriction is effectively antagonized by pUL97 or pUL21a, a
model that will be fully tested in future studies.
WHY TARGET THE APC?
Even though definitive evidence is still lacking in most viral sys-
tems, identification of a number of viral APC regulators from
diverse virus families, together with the recent study on HCMV
(7), provides appealing evidence that APC activity plays an impor-
tant role in virus replication and pathogenesis. What are the ben-
efits for viruses to modulate the APC? For HTLV-1 and HBV,
premature activation of APCCdc20may induce chromosome insta-
bility and contribute to their tumorigenic ability. Other viruses
may inhibit APCCdh1 to promote an S-phase-like environment or
APCCdc20 to prevent reformation of the nuclear envelope, so nu-
clear factors become enriched or accessible for virus replication.
As the APC targets more than 30 proteins for ubiquitination and
degradation, inhibition of this complex would stabilize its sub-
strates, any one of which may be important for virus replication
(Fig. 3). Interestingly, within poxvirus and herpesvirus families,
the only viruses that have been found to modulate the APC are
parapoxviruses and HCMV. These two viruses do not encode
their own thymidine kinase (TK) and ribonucleotide reductase
(RRM2) enzymes (60, 67). Both enzymes are APC substrates and
critical for the production of deoxyribonucleotides. It seems plau-
sible that APC regulation may be one mechanism used by these
viruses to accumulate sufficient nucleotides for viral genome am-
plification, even though this has not been experimentally tested.
Finally, the APC may also restrict viral replication by targeting
viral proteins for ubiquitination and degradation. This is exem-
plified by the facts that the bovine papillomavirus replicative he-
licase E1 is targeted by the APC (72) and that several HCMV
proteins contain the consensus D box, an APC recognition signal
commonly found in its substrates (65). The precise mechanism
may differ for different viruses, but a common theme is that these
viral regulators are key components of the invasive strategy for
viruses to overcome direct and indirect effects of the APC on their
infection.
FUTURE PERSPECTIVE
At least nine proteins from diverse viral families have now been
reported tomodulate the function of the APC, andmore are likely
to be discovered, highlighting the potential importance of this cell
cycle master regulator in virus infection. The major limitation is
that the data from most of these studies are correlative at best. In
many cases, it has not been shown that theAPC is regulated during
virus infection, and in several cases, the mechanism has not been
clearly defined. The potential role of virus-mediated APC regula-
tion during infection is largely unknown, an issue further compli-
cated by the fact that most of the identified viral APC regulators
have other known functions. Future studies should focus on iden-
tifying the mechanisms that these proteins use to regulate the
APC, determining whether or not they function during virus in-
fection, and providing definitive evidence of whether and how the
APC is involved in virus replication and pathogenesis. In cases in
which the APC restricts virus replication, it will be important to
determine whether the APC plays its role by acting on viral or
cellular substrates. It will be important to identify the APC sub-
strates that conversely act to promote virus replication. For in-
stance, it would be informative to determine whether overexpres-
sion of TK or RRM2 can restore virus replication of HCMV, orf
virus, HPV, or CAV mutants that lack their APC regulators. Fi-
nally, the fact that multiple tumor-inducing viruses (HPV, HBV,
and HTLV-1) encode proteins that regulate the APC raises an
important question ofwhether these viruses useAPC regulation as
a mechanism to promote tumorigenesis, which should be ad-
dressed definitively in future investigations.
Further studies of these viral regulators will also promise to
shed light on the biology of the APC. As has been shown in many
masterpieces of seminal work, viruses are extremely useful tools to
probe the biology of critical cellular proteins (e.g., p53, Rb). Elu-
cidating how these viral proteins interact with the APC will un-
doubtedly enhance our understanding of APC structure, assem-
bly, and regulation.On amore applied side, such studies will likely
have important implications for cancer research, exemplified by
the fact that drugs are now being developed to target the APC for
anticancer therapy (8). These viral proteins are invaluable tools to
identify key features of the APC that can be used as additional
targets for novel drugs. Apoptin is currently being investigated as
a potential cancer therapy due to its ability to selectively kill tumor
cells, and other viral APC regulators are likely to have similar
qualities. For instance, expression of E4orf4, E2, or PACR also has
a dramatic effect on cell cycle progress (39, 40, 53, 60, 61). Fur-
thermore, pUL21a overexpression prevented the proliferative
ability of a transformed cell line (7), suggesting that pUL21a reg-
ulation of the APC may inhibit cancer cell growth. Conversely,
HPV E2 andHBVX proteins may facilitate tumorigenesis in their
respective virus systems and thus may be attractive drug targets to
prevent certain types of viral-induced cancer. Future work should
strive to gain an understanding of intricate interplays among the
APC, virus replication, cell cycle, and virus-induced cancer.
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